within Pharmacolibrary.Drugs.ATC.J;

model J04AM02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.89,
    Cl             = 0.00021666666666666666,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.07,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 900
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J04AM02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Rifampicin and isoniazid is a fixed-dose combination medication used primarily in the treatment of tuberculosis. Rifampicin acts by inhibiting DNA-dependent RNA polymerase in bacterial cells, while isoniazid interferes with mycolic acid synthesis in the Mycobacterium tuberculosis cell wall. This combination is recommended by the World Health Organization and is included in essential medicines lists globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult patient, as published population PK models for the fixed-dose combination are limited. Parameters are based on literature-reported values of rifampicin and isoniazid administered orally.</p><h4>References</h4><ol><li><p>Sullins, AK, &amp; Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. <i>Paediatric drugs</i> 15(2) 93–117. DOI:<a href=\"https://doi.org/10.1007/s40272-013-0017-5\">10.1007/s40272-013-0017-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23529866/\">https://pubmed.ncbi.nlm.nih.gov/23529866</a></p></li><li><p>Sibley, L, et al., &amp; Sharpe, S (2022). Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of . <i>Pharmaceutics</i> 14(12) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics14122666\">10.3390/pharmaceutics14122666</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36559163/\">https://pubmed.ncbi.nlm.nih.gov/36559163</a></p></li><li><p>Loos, U, et al., &amp; Eichelbaum, M (1985). Pharmacokinetics of oral and intravenous rifampicin during chronic administration. <i>Klinische Wochenschrift</i> 63(23) 1205–1211. DOI:<a href=\"https://doi.org/10.1007/BF01733779\">10.1007/BF01733779</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4087830/\">https://pubmed.ncbi.nlm.nih.gov/4087830</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J04AM02;
